English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Tuberculosis (TB) is an infection caused by  Mycobacterium tuberculosis , responsible for 1.66 million documented deaths in 2020. The increase in reported cases of  M. tuberculosis  resistance to the main drugs shows the need to develop new and efficient drugs for better TB control. A strategy to overcome the resistance problem could be the polypharmacology approach, whereby researchers develop a single molecule that acts on different targets. Polypharmacology could have features that make it more effective than classical polypharmacy, in which investigators pull various drugs with high affinity for one target together. Based on the effectiveness of multitargeting, this work aimed to use combined in silico techniques to identify potential dual inhibitors for Pantothenate Kinases (PanK) and CTP synthetase PyrG. In silico drug design allows for screening of potential leads, thus decreasing time and resource consumption. This study demonstrates an optimised and proven screening technique to discover a potential small-molecule inhibitor of  Mycobacterium tuberculosis  PanK and PyrG. The favourable binding free energy values and interaction profiles show ZINC53995076 as a potent dual inhibitor of the  Mycobacterium tuberculosis  PanK and PyrG.

Pharmacophore mapping of the crucial mediators of dual inhibitor activity of PanK and PyrG in tuberculosis disease